Precision BioSciences, Inc. (DTIL) News
Filter DTIL News Items
DTIL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DTIL News Highlights
- 500 - Internal server error
- Over the past 12 days, the trend for DTIL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about DTIL are VIVO and GENE.
Latest DTIL News From Around the Web
Below are the latest news stories about Precision Biosciences Inc that investors may wish to consider to help them evaluate DTIL as an investment opportunity.
Precision Bio's chief operating officer resignsPrecision BioSciences (DTIL) chief operating officer David Thomson, Ph.D., notified the Company of his resignation, effective July 2.The Company will reassign the duties of the COO to other members of the management and senior management team and use this opportunity to restructure the role in the organization.([[DTIL]] +3.8%)Previously (June 4):... |
Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin LymphomaPrecision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced encouraging progress on two strategies designed to optimize the durability of allogeneic CAR T therapy in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). The Company reported updated interim results from its Phase 1/2a study of PBCAR0191, the Company’s investigational, off-t |
Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In VivoPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced a new paper published online in Nature Communications that reports preclinical results using an ARCUS nuclease to target mitochondrial DNA (mtDNA) and reduce levels of mutant mtDNA in vivo. |
Precision BioSciences Appoints Alex Kelly as Chief Financial OfficerPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced the appointment of Alex Kelly as Chief Financial Officer. Alex joined Precision BioSciences in October 2020 as Chief Corporate Affairs Officer and has served as the company’s Interim Chief Financial Officer since December 2020. He will continue to serve as the company’s principal financial officer, reporting directly to Matt Kane, Chief Executive Officer and oversee the company’s finance, corporate communications, and investor relations functions. Shane Barton, the Company’s Vice President and Corporate Controller, has been serving as interim principal accounting officer and will now ... |
Precision BioSciences to Participate in the Jefferies Virtual Healthcare ConferencePrecision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and co-founder, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference being held from June 1-4, 2021. |
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue EstimatesPrecision BioSciences (DTIL) delivered earnings and revenue surprises of 32.65% and 86.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock? |
Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business UpdatePrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. |
Precision BioSciences to Report First Quarter 2021 Financial Results on May 13, 2021Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it will publish first quarter 2021 financial results and provide a business update on Thursday, May 13, 2021. |
Precision BioSciences Announces Poster Presentation at the Upcoming American Society of Gene & Cell Therapy Annual MeetingPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced that the following poster, highlighting a preclinical research collaboration using its ARCUS® genome editing platform for treatment of transthyretin amyloidosis (ATTR), will be presented at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, scheduled for May 11-14, 2021. |
Precision BioSciences Appoints Stanley R. Frankel, M.D. to Board of DirectorsStanley R. Frankel, M.D. has been appointed to the Board of Directors for Precision BioSciences. |